Every 10-Q that Azitra Inc (AZTR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AZTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AZTR filings page.
Azitra, Inc. is a pre-commercial synthetic biology company developing precision dermatology therapies using engineered microbes and proteins. For the six months ended June 30, 2026, it reported a net loss of $7.27 million, with operating expenses of $7.35 million and no product revenue. Operating cash use was $5.77 million, reflecting ongoing R&D and G&A spending.
Cash and cash equivalents rose to $6.73 million from $2.07 million at year-end 2025, driven mainly by a $10.4 million Series A preferred financing, warrant exercises and draws on an Equity Line of Credit, bringing total assets to $8.92 million and stockholders’ equity to $7.33 million. Shares outstanding increased to 60,603,742, and warrants outstanding reached 219,470,313, indicating significant potential dilution. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing cumulative losses of about $75.8 million and the need for additional financing despite current cash and access to approximately $13.8 million remaining under the Equity Line of Credit. Azitra also notes that its current equity level exceeds NYSE American minimums, though it remains under an exchange compliance plan.
Azitra, Inc. reported a net loss of $3.9 million for the quarter ended March 31, 2026, compared with $3.1 million a year earlier, as it continues pre‑revenue development of precision dermatology therapies.
Cash and cash equivalents rose to $10.1 million from $2.1 million at December 31, 2025, mainly from a $10.4 million Series A preferred financing and draws on an equity line of credit. Stockholders’ equity increased to $10.5 million, but the company has an accumulated deficit of about $72.4 million and used $2.5 million of cash in operating activities this quarter.
Management states there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months without additional financing. Azitra also remains subject to NYSE American continued listing requirements after previously receiving a deficiency notice, and is relying on equity offerings, an equity line of credit with up to $20 million capacity, and newly issued Series A preferred stock and large warrant packages that could convert into or be exercisable for hundreds of millions of common shares.
Azitra, Inc. (AZTR) filed its Q3 2025 report, showing no revenue and a net loss of $2.8 million for the quarter. Operating expenses were $2.8 million (G&A $1.59 million; R&D $1.18 million). Year to date, the company reported a net loss of $8.7 million and used $8.3 million in operating cash.
Cash and cash equivalents were $1.4 million with stockholders’ equity of $2.3 million as of September 30, 2025. Shares outstanding were 5,604,938 as of September 30, 2025; the company reported 10,204,938 shares outstanding as of November 11, 2025. Azitra drew on a $20 million equity line of credit, issuing 7,955,823 shares and 795,579 warrants for gross proceeds of $6.0 million, with approximately $14.0 million remaining available as of November 12, 2025.
NYSE American issued a deficiency notice on October 1, 2025, citing stockholders’ equity below $4.0 million; Azitra submitted a compliance plan. Management disclosed substantial doubt about going concern due to the accumulated deficit of $66.3 million, ongoing losses, and limited working capital of $0.4 million. The company effected reverse stock splits in 2024 and 2025 and increased authorized common shares to support capital-raising.
Azitra, Inc. reported continuing pre‑commercial operations and clinical progress while facing significant financing pressure. For the six months ended June 30, 2025 the company recorded a net loss of $5.96 million, used $5.89 million of cash in operating activities and ended the period with $1.05 million of cash. Total assets declined to $3.96 million from $7.36 million at year-end 2024, and working capital was approximately $0.3 million, contributing to management's conclusion of substantial doubt about the company's ability to continue as a going concern.
The company advanced its development programs: ATR-12 dosed its first patient in August 2024 with initial safety results reported in H1 2025; ATR-04 received IND clearance and Fast Track designation and is expected to dose its first patient in Q3 2025; ATR-01 remains in lead optimization with an IND targeted for 2026. On April 24, 2025 Azitra established a $20 million equity line of credit (ELOC) with Alumni Capital, issued shares and warrants under the ELOC and reported gross proceeds of $1.7 million, with $18.3 million available under the facility as of August 11, 2025.